PTO/SB/08b (07-09)

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of \$25, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449 ATRACEMENT & TRACEMENT			EMP	Complete if Known			
W/& THAN				Application Number	10/579,705		
INFO	ORMATION	DIS	CLOSURE	Filing Date	October 31, 2008		
STATEMENT BY APPLICANT				First Named Inventor	George J. Christ		
(Use as many sheets as necessary)				Art Unit	1633		
				Examiner Name	Quang Nguyen, Ph.D.		
Sheet	1	of	2	Attorney Docket Number	96700/1139		

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*				
	1	FOSTER D N et al., Positive and Negative cis-Acting Regulatory Elements Mediate Expression of the Mouse Vascular Smooth Muscle alpha-Action Gene, The Journal of Blological		
		Chemistry, June 15, 1992, Vol. 267, NO. 17, pp. 11995-12003.		
	2	CHANG P C et al., Muscle Specificity Encoded by Specific Serum Response, The Journal of Biological Chemistry, May 18, 2001, Vol. 276, No. 20, pp. 17206-17212.		
Surgery, Japan, Vol. 14, No. 11, pp. 1221-1226, November 15, 2001.  SATO Y et al., Male Sexual Dysfunctions, treatment for erectile disorder, "Gene tand tissue engineering for erectile dysfunction," Male Sexual Dysfunctions, Japan		SATO Y, The current situation and the future for ED treatment, Urological Surgery, Japan, Vol. 14, No. 11, pp. 1221-1226, November 15, 2001.		
		SATO Y et al., Male Sexual Dysfunctions, treatment for erectile disorder, "Gene therapy and tissue engineering for erectile dysfunction," Male Sexual Dysfunctions, Japanese		
		Journal of Clinical Medicine, Japan, Vol. 60, Extra No. 6, pp. 310-314, June 28, 2002.		
	5	SATO Y et al., Gene Therapy with Maxi-K+ Channels Restores Diminished Erectile Resposne in Older Animals During Electrical Stimulation of the Medial Preoptic Area (MPOA), The		
		Journal of Urology, 2000, Vol. 163, No. 4, Supplement, pp. 198-199.		
	6	SATO Y et al., The Effects of Gene Therapy with Maxi-K+ Channels Apomorphine-Evoked Increases in Intracavernous Pressure in the Awake Rats, The		
		Journal of Urology, 2001, Vol. 165, No. 5, Supplement, p. 220.		

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (07-09)

Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known				
- Caroniale 161 161111   1446/1   16				Application Number	10/579,705	
INF	ORMATIC	ON DIS	CLOSURE	Filing Date	October 31, 2008	
STATEMENT BY APPLICANT				First Named Inventor	George J. Christ	
	(llea se man	, choote se n	ocossani)	Art Unit	1633	
(Use as many sheets as necessary)			ecessary)	Examiner Name	Quang Nguyen, Ph.D.	
Sheet	1	of	2	Attorney Docket Number	96700/1139	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	- The state of the		
	7	THORNE G D et al., Hypoxic vasorelaxation inhibition by organ culture correlates with loss of Kv channels but not Ca2+ channels, American Journal of	
		Physiology-Heart and Circulatory Physiology, July 2002, Vol. 283, No. 1, Pt. 2, pp. H247-H253.	
	8	KIMURA et al., Analysis of pathogeny for arteriosity erectile dysfunction "Smooth muscle content in corpus cavornosum penis and the relaxant response" Summary for conference	
		presentation in the Pharmaceutical Society of Japan, Vol. 123rd, No. 4, p. 34, March 5, 2003.	
	9	UEBELE V N et al., Functional Differences in Kvl.5 Currents Expressed in Mammalian Cell Lines Are Due to the Presence of Endogeneous Kv B2. 1 Subunits, The Journal of	
		Biological Chemistry, February 2, 1996, Vol. 271, No. 5, PP. 2406-2412.	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.